Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company announced that the first human patients have been treated with NB1, marking an important milestone for BBLG.
